We performed immunohistochemical staining using antibodies targeting the apelin receptor and the peptides, apelin and ELA, in the presence of a panel of cell markers to assess whether this GPCR and its endogenous ligands are expressed in the diverse stem cell populations that drive glioblastoma pathogenesis and therapeutic resistance (Figure 1). Here, APLN is linked to glioblastoma.